Galmed Pharmaceuticals Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced net loss was USD 8.396 million compared to USD 5.526 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.26 a year ago. For the half year, net loss was USD 17.301 million compared to USD 11.589 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.55 a year ago.